georgie18
4 weeks ago
CYCN...$6.05...🥳...Off my $3.24 Alert...
georgie18
Member Level
Re: georgie18 post# 31425
Monday, February 03, 2025 2:09:38 PM
Post#
31429
of 31433
CYCN...$5.68...HOD...🥳...off my $3.24 Alert...
georgie18
Member Level
Re: georgie18 post# 673136
Monday, February 03, 2025 1:54:57 PM
Post#
673150
of 673155
CYCN...$5.13 On the breakout...🥳...Off my $3.24 Alert...
georgie18
Member Level
Re: georgie18 post# 31398
Monday, February 03, 2025 12:30:04 PM
Post#
31405
of 31424
CYCN...$4.97...Hit $5.20...HOD...🥳...off my $3.24Alert...
georgie18
Member Level
Re: georgie18 post# 673098
Monday, February 03, 2025 12:09:45 PM
Post#
673129
of 673135
CYCN...$4.72...Off my $3.24 Alert...🥳
georgie18
Member Level
Re: georgie18 post# 31270
Monday, February 03, 2025 8:27:19 AM
Post#
31363
of 31397
CYCN...$4.58...🥳
georgie18
Member Level
Re: georgie18 post# 672920
Friday, January 31, 2025 9:55:17 AM
Post#
672926
of 673097
CYCN...$4.47...HOD...🥳...2 Million Range Float...
georgie18
Member Level
Re: tw0122 post# 31264
Friday, January 31, 2025 9:44:57 AM
Post#
31265
of 31268
CYCN...$4.09...Off my $3.24 Alert...Price catching up to the News here...🥳
georgie18
Member Level
Re: georgie18 post# 670922
Thursday, January 30, 2025 8:01:17 PM
Post#
672876
of 672918
CYCN...$3.80...🥳...Off my $3.24 Alert...
georgie18
Member Level
Re: None
Thursday, January 09, 2025 9:18:16 AM
Post#
73
of 74
CYCN...$3.24...🥳... https://schrts.co/BZqjIquT ...Float in 2 Million range...CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced an update on its progress in catalyzing the Companyās next stage of growth. The Company is leveraging its legacy soluble guanylate cyclase (sGC) stimulator assets to generate near-term revenues which will be used to implement its strategic building plan without near-term dilution.
āThese agreements demonstrate Cyclerionās progress in maximizing its legacy asset value while redirecting resources toward acquiring potential new assets,ā said Regina Graul, Ph.D., President and Chief Executive Officer of Cyclerion. āThese newly finalized agreements, combined with our significant reduction of operating expenses, enable the focused use of our capital to support our anticipated pipeline build in the central nervous system (CNS) space. Concurrently, we plan to raise capital, as needed, to fund our product plans to create value for shareholders and patients.ā Graul continued, āCyclerionās diligence team, comprised of committed external experts in their respective fields, is currently in advanced stages of conducting promising asset evaluations, which we believe have the potential to be the new foundation for Cyclerion.ā
Cyclerion and Akebia have re-negotiated a mutually beneficial amendment to their exclusive license agreement for praliciguat, a systemic sGC stimulator. Under the new license amendment with Akebia, Cyclerion will receive $1.75 million in upfront and near-term payments. In addition, Akebia will assume responsibility for all intellectual property expenses associated with praliciguat after Q1 2025. In 2021, Akebia paid a $3.0 million upfront payment to the Company upon signing of the license agreement, and the Company is eligible to receive additional milestone cash payments of up to approximately $560 million in total potential future development, regulatory, and commercialization milestone payments for praliciguat. In exchange for a reduction in certain development milestone payments, Cyclerion is eligible to receive certain higher, tiered, sales-based royalties ranging from mid-single-digits to twenty percent.
Cyclerion has also entered into an exclusive license option agreement for its vascular sGC stimulator, olinciguat, with a separate entity, wholly controlled by CVCO Therapeutics, Inc., a clinical stage company focused on microvascular dysfunction in cardiovascular, inflammatory and metabolic disease states. Under the terms of the agreement, the potential partner has exclusive rights to evaluate olinciguat during the option period. During the option period, the grantee has assumed responsibility for all ongoing intellectual property-related expenses associated with olinciguat.
As part of its strategic initiatives, Cyclerion previously announced a definitive agreement for the sale of its CNS assets zagociguat and CY3018 to Tisento Therapeutics in May 2023 for an $8 million cash payment and a 10% equity stake in Tisento. The amended agreement for praliciguat, and if the option for olinciguat is exercised, would represent the likely final steps in the monetization of Cyclerionās historical portfolio. Cyclerion believes it is well positioned for the next phase in its overall strategy, to bring in new CNS assets to rebuild the pipeline.
georgie18
4 weeks ago
CYCN...$5.68...HOD...🥳...off my $3.24 Alert...
georgie18
Member Level
Re: georgie18 post# 673136
Monday, February 03, 2025 1:54:57 PM
Post#
673150
of 673155
CYCN...$5.13 On the breakout...🥳...Off my $3.24 Alert...
georgie18
Member Level
Re: georgie18 post# 31398
Monday, February 03, 2025 12:30:04 PM
Post#
31405
of 31424
CYCN...$4.97...Hit $5.20...HOD...🥳...off my $3.24Alert...
georgie18
Member Level
Re: georgie18 post# 673098
Monday, February 03, 2025 12:09:45 PM
Post#
673129
of 673135
CYCN...$4.72...Off my $3.24 Alert...🥳
georgie18
Member Level
Re: georgie18 post# 31270
Monday, February 03, 2025 8:27:19 AM
Post#
31363
of 31397
CYCN...$4.58...🥳
georgie18
Member Level
Re: georgie18 post# 672920
Friday, January 31, 2025 9:55:17 AM
Post#
672926
of 673097
CYCN...$4.47...HOD...🥳...2 Million Range Float...
georgie18
Member Level
Re: tw0122 post# 31264
Friday, January 31, 2025 9:44:57 AM
Post#
31265
of 31268
CYCN...$4.09...Off my $3.24 Alert...Price catching up to the News here...🥳
georgie18
Member Level
Re: georgie18 post# 670922
Thursday, January 30, 2025 8:01:17 PM
Post#
672876
of 672918
CYCN...$3.80...🥳...Off my $3.24 Alert...
georgie18
Member Level
Re: None
Thursday, January 09, 2025 9:18:16 AM
Post#
73
of 74
CYCN...$3.24...🥳... https://schrts.co/BZqjIquT ...Float in 2 Million range...CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced an update on its progress in catalyzing the Companyās next stage of growth. The Company is leveraging its legacy soluble guanylate cyclase (sGC) stimulator assets to generate near-term revenues which will be used to implement its strategic building plan without near-term dilution.
āThese agreements demonstrate Cyclerionās progress in maximizing its legacy asset value while redirecting resources toward acquiring potential new assets,ā said Regina Graul, Ph.D., President and Chief Executive Officer of Cyclerion. āThese newly finalized agreements, combined with our significant reduction of operating expenses, enable the focused use of our capital to support our anticipated pipeline build in the central nervous system (CNS) space. Concurrently, we plan to raise capital, as needed, to fund our product plans to create value for shareholders and patients.ā Graul continued, āCyclerionās diligence team, comprised of committed external experts in their respective fields, is currently in advanced stages of conducting promising asset evaluations, which we believe have the potential to be the new foundation for Cyclerion.ā
Cyclerion and Akebia have re-negotiated a mutually beneficial amendment to their exclusive license agreement for praliciguat, a systemic sGC stimulator. Under the new license amendment with Akebia, Cyclerion will receive $1.75 million in upfront and near-term payments. In addition, Akebia will assume responsibility for all intellectual property expenses associated with praliciguat after Q1 2025. In 2021, Akebia paid a $3.0 million upfront payment to the Company upon signing of the license agreement, and the Company is eligible to receive additional milestone cash payments of up to approximately $560 million in total potential future development, regulatory, and commercialization milestone payments for praliciguat. In exchange for a reduction in certain development milestone payments, Cyclerion is eligible to receive certain higher, tiered, sales-based royalties ranging from mid-single-digits to twenty percent.
Cyclerion has also entered into an exclusive license option agreement for its vascular sGC stimulator, olinciguat, with a separate entity, wholly controlled by CVCO Therapeutics, Inc., a clinical stage company focused on microvascular dysfunction in cardiovascular, inflammatory and metabolic disease states. Under the terms of the agreement, the potential partner has exclusive rights to evaluate olinciguat during the option period. During the option period, the grantee has assumed responsibility for all ongoing intellectual property-related expenses associated with olinciguat.
As part of its strategic initiatives, Cyclerion previously announced a definitive agreement for the sale of its CNS assets zagociguat and CY3018 to Tisento Therapeutics in May 2023 for an $8 million cash payment and a 10% equity stake in Tisento. The amended agreement for praliciguat, and if the option for olinciguat is exercised, would represent the likely final steps in the monetization of Cyclerionās historical portfolio. Cyclerion believes it is well positioned for the next phase in its overall strategy, to bring in new CNS assets to rebuild the pipeline.
georgie18
4 weeks ago
CYCN...$5.13 On the breakout...🥳...Off my $3.24 Alert...
georgie18
Member Level
Re: georgie18 post# 31398
Monday, February 03, 2025 12:30:04 PM
Post#
31405
of 31424
CYCN...$4.97...Hit $5.20...HOD...🥳...off my $3.24Alert...
georgie18
Member Level
Re: georgie18 post# 673098
Monday, February 03, 2025 12:09:45 PM
Post#
673129
of 673135
CYCN...$4.72...Off my $3.24 Alert...🥳
georgie18
Member Level
Re: georgie18 post# 31270
Monday, February 03, 2025 8:27:19 AM
Post#
31363
of 31397
CYCN...$4.58...🥳
georgie18
Member Level
Re: georgie18 post# 672920
Friday, January 31, 2025 9:55:17 AM
Post#
672926
of 673097
CYCN...$4.47...HOD...🥳...2 Million Range Float...
georgie18
Member Level
Re: tw0122 post# 31264
Friday, January 31, 2025 9:44:57 AM
Post#
31265
of 31268
CYCN...$4.09...Off my $3.24 Alert...Price catching up to the News here...🥳
georgie18
Member Level
Re: georgie18 post# 670922
Thursday, January 30, 2025 8:01:17 PM
Post#
672876
of 672918
CYCN...$3.80...🥳...Off my $3.24 Alert...
georgie18
Member Level
Re: None
Thursday, January 09, 2025 9:18:16 AM
Post#
73
of 74
CYCN...$3.24...🥳... https://schrts.co/BZqjIquT ...Float in 2 Million range...CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced an update on its progress in catalyzing the Companyās next stage of growth. The Company is leveraging its legacy soluble guanylate cyclase (sGC) stimulator assets to generate near-term revenues which will be used to implement its strategic building plan without near-term dilution.
āThese agreements demonstrate Cyclerionās progress in maximizing its legacy asset value while redirecting resources toward acquiring potential new assets,ā said Regina Graul, Ph.D., President and Chief Executive Officer of Cyclerion. āThese newly finalized agreements, combined with our significant reduction of operating expenses, enable the focused use of our capital to support our anticipated pipeline build in the central nervous system (CNS) space. Concurrently, we plan to raise capital, as needed, to fund our product plans to create value for shareholders and patients.ā Graul continued, āCyclerionās diligence team, comprised of committed external experts in their respective fields, is currently in advanced stages of conducting promising asset evaluations, which we believe have the potential to be the new foundation for Cyclerion.ā
Cyclerion and Akebia have re-negotiated a mutually beneficial amendment to their exclusive license agreement for praliciguat, a systemic sGC stimulator. Under the new license amendment with Akebia, Cyclerion will receive $1.75 million in upfront and near-term payments. In addition, Akebia will assume responsibility for all intellectual property expenses associated with praliciguat after Q1 2025. In 2021, Akebia paid a $3.0 million upfront payment to the Company upon signing of the license agreement, and the Company is eligible to receive additional milestone cash payments of up to approximately $560 million in total potential future development, regulatory, and commercialization milestone payments for praliciguat. In exchange for a reduction in certain development milestone payments, Cyclerion is eligible to receive certain higher, tiered, sales-based royalties ranging from mid-single-digits to twenty percent.
Cyclerion has also entered into an exclusive license option agreement for its vascular sGC stimulator, olinciguat, with a separate entity, wholly controlled by CVCO Therapeutics, Inc., a clinical stage company focused on microvascular dysfunction in cardiovascular, inflammatory and metabolic disease states. Under the terms of the agreement, the potential partner has exclusive rights to evaluate olinciguat during the option period. During the option period, the grantee has assumed responsibility for all ongoing intellectual property-related expenses associated with olinciguat.
As part of its strategic initiatives, Cyclerion previously announced a definitive agreement for the sale of its CNS assets zagociguat and CY3018 to Tisento Therapeutics in May 2023 for an $8 million cash payment and a 10% equity stake in Tisento. The amended agreement for praliciguat, and if the option for olinciguat is exercised, would represent the likely final steps in the monetization of Cyclerionās historical portfolio. Cyclerion believes it is well positioned for the next phase in its overall strategy, to bring in new CNS assets to rebuild the pipeline.
georgie18
4 weeks ago
CYCN...$4.97...Hit $5.20...HOD...🥳...off my $3.24Alert...
georgie18
Member Level
Re: georgie18 post# 673098
Monday, February 03, 2025 12:09:45 PM
Post#
673129
of 673135
CYCN...$4.72...Off my $3.24 Alert...🥳
georgie18
Member Level
Re: georgie18 post# 31270
Monday, February 03, 2025 8:27:19 AM
Post#
31363
of 31397
CYCN...$4.58...🥳
georgie18
Member Level
Re: georgie18 post# 672920
Friday, January 31, 2025 9:55:17 AM
Post#
672926
of 673097
CYCN...$4.47...HOD...🥳...2 Million Range Float...
georgie18
Member Level
Re: tw0122 post# 31264
Friday, January 31, 2025 9:44:57 AM
Post#
31265
of 31268
CYCN...$4.09...Off my $3.24 Alert...Price catching up to the News here...🥳
georgie18
Member Level
Re: georgie18 post# 670922
Thursday, January 30, 2025 8:01:17 PM
Post#
672876
of 672918
CYCN...$3.80...🥳...Off my $3.24 Alert...
georgie18
Member Level
Re: None
Thursday, January 09, 2025 9:18:16 AM
Post#
73
of 74
CYCN...$3.24...🥳... https://schrts.co/BZqjIquT ...Float in 2 Million range...CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced an update on its progress in catalyzing the Companyās next stage of growth. The Company is leveraging its legacy soluble guanylate cyclase (sGC) stimulator assets to generate near-term revenues which will be used to implement its strategic building plan without near-term dilution.
āThese agreements demonstrate Cyclerionās progress in maximizing its legacy asset value while redirecting resources toward acquiring potential new assets,ā said Regina Graul, Ph.D., President and Chief Executive Officer of Cyclerion. āThese newly finalized agreements, combined with our significant reduction of operating expenses, enable the focused use of our capital to support our anticipated pipeline build in the central nervous system (CNS) space. Concurrently, we plan to raise capital, as needed, to fund our product plans to create value for shareholders and patients.ā Graul continued, āCyclerionās diligence team, comprised of committed external experts in their respective fields, is currently in advanced stages of conducting promising asset evaluations, which we believe have the potential to be the new foundation for Cyclerion.ā
Cyclerion and Akebia have re-negotiated a mutually beneficial amendment to their exclusive license agreement for praliciguat, a systemic sGC stimulator. Under the new license amendment with Akebia, Cyclerion will receive $1.75 million in upfront and near-term payments. In addition, Akebia will assume responsibility for all intellectual property expenses associated with praliciguat after Q1 2025. In 2021, Akebia paid a $3.0 million upfront payment to the Company upon signing of the license agreement, and the Company is eligible to receive additional milestone cash payments of up to approximately $560 million in total potential future development, regulatory, and commercialization milestone payments for praliciguat. In exchange for a reduction in certain development milestone payments, Cyclerion is eligible to receive certain higher, tiered, sales-based royalties ranging from mid-single-digits to twenty percent.
Cyclerion has also entered into an exclusive license option agreement for its vascular sGC stimulator, olinciguat, with a separate entity, wholly controlled by CVCO Therapeutics, Inc., a clinical stage company focused on microvascular dysfunction in cardiovascular, inflammatory and metabolic disease states. Under the terms of the agreement, the potential partner has exclusive rights to evaluate olinciguat during the option period. During the option period, the grantee has assumed responsibility for all ongoing intellectual property-related expenses associated with olinciguat.
As part of its strategic initiatives, Cyclerion previously announced a definitive agreement for the sale of its CNS assets zagociguat and CY3018 to Tisento Therapeutics in May 2023 for an $8 million cash payment and a 10% equity stake in Tisento. The amended agreement for praliciguat, and if the option for olinciguat is exercised, would represent the likely final steps in the monetization of Cyclerionās historical portfolio. Cyclerion believes it is well positioned for the next phase in its overall strategy, to bring in new CNS assets to rebuild the pipeline.
georgie18
4 weeks ago
CYCN...$4.72...Off my $3.24 Alert...🥳
georgie18
Member Level
Re: georgie18 post# 31270
Monday, February 03, 2025 8:27:19 AM
Post#
31363
of 31397
CYCN...$4.58...🥳
georgie18
Member Level
Re: georgie18 post# 672920
Friday, January 31, 2025 9:55:17 AM
Post#
672926
of 673097
CYCN...$4.47...HOD...🥳...2 Million Range Float...
georgie18
Member Level
Re: tw0122 post# 31264
Friday, January 31, 2025 9:44:57 AM
Post#
31265
of 31268
CYCN...$4.09...Off my $3.24 Alert...Price catching up to the News here...🥳
georgie18
Member Level
Re: georgie18 post# 670922
Thursday, January 30, 2025 8:01:17 PM
Post#
672876
of 672918
CYCN...$3.80...🥳...Off my $3.24 Alert...
georgie18
Member Level
Re: None
Thursday, January 09, 2025 9:18:16 AM
Post#
73
of 74
CYCN...$3.24...🥳... https://schrts.co/BZqjIquT ...Float in 2 Million range...CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced an update on its progress in catalyzing the Companyās next stage of growth. The Company is leveraging its legacy soluble guanylate cyclase (sGC) stimulator assets to generate near-term revenues which will be used to implement its strategic building plan without near-term dilution.
āThese agreements demonstrate Cyclerionās progress in maximizing its legacy asset value while redirecting resources toward acquiring potential new assets,ā said Regina Graul, Ph.D., President and Chief Executive Officer of Cyclerion. āThese newly finalized agreements, combined with our significant reduction of operating expenses, enable the focused use of our capital to support our anticipated pipeline build in the central nervous system (CNS) space. Concurrently, we plan to raise capital, as needed, to fund our product plans to create value for shareholders and patients.ā Graul continued, āCyclerionās diligence team, comprised of committed external experts in their respective fields, is currently in advanced stages of conducting promising asset evaluations, which we believe have the potential to be the new foundation for Cyclerion.ā
Cyclerion and Akebia have re-negotiated a mutually beneficial amendment to their exclusive license agreement for praliciguat, a systemic sGC stimulator. Under the new license amendment with Akebia, Cyclerion will receive $1.75 million in upfront and near-term payments. In addition, Akebia will assume responsibility for all intellectual property expenses associated with praliciguat after Q1 2025. In 2021, Akebia paid a $3.0 million upfront payment to the Company upon signing of the license agreement, and the Company is eligible to receive additional milestone cash payments of up to approximately $560 million in total potential future development, regulatory, and commercialization milestone payments for praliciguat. In exchange for a reduction in certain development milestone payments, Cyclerion is eligible to receive certain higher, tiered, sales-based royalties ranging from mid-single-digits to twenty percent.
Cyclerion has also entered into an exclusive license option agreement for its vascular sGC stimulator, olinciguat, with a separate entity, wholly controlled by CVCO Therapeutics, Inc., a clinical stage company focused on microvascular dysfunction in cardiovascular, inflammatory and metabolic disease states. Under the terms of the agreement, the potential partner has exclusive rights to evaluate olinciguat during the option period. During the option period, the grantee has assumed responsibility for all ongoing intellectual property-related expenses associated with olinciguat.
As part of its strategic initiatives, Cyclerion previously announced a definitive agreement for the sale of its CNS assets zagociguat and CY3018 to Tisento Therapeutics in May 2023 for an $8 million cash payment and a 10% equity stake in Tisento. The amended agreement for praliciguat, and if the option for olinciguat is exercised, would represent the likely final steps in the monetization of Cyclerionās historical portfolio. Cyclerion believes it is well positioned for the next phase in its overall strategy, to bring in new CNS assets to rebuild the pipeline.
georgie18
4 weeks ago
CYCN...$4.58...🥳
georgie18
Member Level
Re: georgie18 post# 672920
Friday, January 31, 2025 9:55:17 AM
Post#
672926
of 673097
CYCN...$4.47...HOD...🥳...2 Million Range Float...
georgie18
Member Level
Re: tw0122 post# 31264
Friday, January 31, 2025 9:44:57 AM
Post#
31265
of 31268
CYCN...$4.09...Off my $3.24 Alert...Price catching up to the News here...🥳
georgie18
Member Level
Re: georgie18 post# 670922
Thursday, January 30, 2025 8:01:17 PM
Post#
672876
of 672918
CYCN...$3.80...🥳...Off my $3.24 Alert...
georgie18
Member Level
Re: None
Thursday, January 09, 2025 9:18:16 AM
Post#
73
of 74
CYCN...$3.24...🥳... https://schrts.co/BZqjIquT ...Float in 2 Million range...CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced an update on its progress in catalyzing the Companyās next stage of growth. The Company is leveraging its legacy soluble guanylate cyclase (sGC) stimulator assets to generate near-term revenues which will be used to implement its strategic building plan without near-term dilution.
āThese agreements demonstrate Cyclerionās progress in maximizing its legacy asset value while redirecting resources toward acquiring potential new assets,ā said Regina Graul, Ph.D., President and Chief Executive Officer of Cyclerion. āThese newly finalized agreements, combined with our significant reduction of operating expenses, enable the focused use of our capital to support our anticipated pipeline build in the central nervous system (CNS) space. Concurrently, we plan to raise capital, as needed, to fund our product plans to create value for shareholders and patients.ā Graul continued, āCyclerionās diligence team, comprised of committed external experts in their respective fields, is currently in advanced stages of conducting promising asset evaluations, which we believe have the potential to be the new foundation for Cyclerion.ā
Cyclerion and Akebia have re-negotiated a mutually beneficial amendment to their exclusive license agreement for praliciguat, a systemic sGC stimulator. Under the new license amendment with Akebia, Cyclerion will receive $1.75 million in upfront and near-term payments. In addition, Akebia will assume responsibility for all intellectual property expenses associated with praliciguat after Q1 2025. In 2021, Akebia paid a $3.0 million upfront payment to the Company upon signing of the license agreement, and the Company is eligible to receive additional milestone cash payments of up to approximately $560 million in total potential future development, regulatory, and commercialization milestone payments for praliciguat. In exchange for a reduction in certain development milestone payments, Cyclerion is eligible to receive certain higher, tiered, sales-based royalties ranging from mid-single-digits to twenty percent.
Cyclerion has also entered into an exclusive license option agreement for its vascular sGC stimulator, olinciguat, with a separate entity, wholly controlled by CVCO Therapeutics, Inc., a clinical stage company focused on microvascular dysfunction in cardiovascular, inflammatory and metabolic disease states. Under the terms of the agreement, the potential partner has exclusive rights to evaluate olinciguat during the option period. During the option period, the grantee has assumed responsibility for all ongoing intellectual property-related expenses associated with olinciguat.
As part of its strategic initiatives, Cyclerion previously announced a definitive agreement for the sale of its CNS assets zagociguat and CY3018 to Tisento Therapeutics in May 2023 for an $8 million cash payment and a 10% equity stake in Tisento. The amended agreement for praliciguat, and if the option for olinciguat is exercised, would represent the likely final steps in the monetization of Cyclerionās historical portfolio. Cyclerion believes it is well positioned for the next phase in its overall strategy, to bring in new CNS assets to rebuild the pipeline.
georgie18
4 weeks ago
CYCN...$4.47...HOD...🥳...2 Million Range Float...
georgie18
Member Level
Re: tw0122 post# 31264
Friday, January 31, 2025 9:44:57 AM
Post#
31265
of 31268
CYCN...$4.09...Off my $3.24 Alert...Price catching up to the News here...🥳
georgie18
Member Level
Re: georgie18 post# 670922
Thursday, January 30, 2025 8:01:17 PM
Post#
672876
of 672918
CYCN...$3.80...🥳...Off my $3.24 Alert...
georgie18
Member Level
Re: None
Thursday, January 09, 2025 9:18:16 AM
Post#
73
of 74
CYCN...$3.24...🥳... https://schrts.co/BZqjIquT ...Float in 2 Million range...CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced an update on its progress in catalyzing the Companyās next stage of growth. The Company is leveraging its legacy soluble guanylate cyclase (sGC) stimulator assets to generate near-term revenues which will be used to implement its strategic building plan without near-term dilution.
āThese agreements demonstrate Cyclerionās progress in maximizing its legacy asset value while redirecting resources toward acquiring potential new assets,ā said Regina Graul, Ph.D., President and Chief Executive Officer of Cyclerion. āThese newly finalized agreements, combined with our significant reduction of operating expenses, enable the focused use of our capital to support our anticipated pipeline build in the central nervous system (CNS) space. Concurrently, we plan to raise capital, as needed, to fund our product plans to create value for shareholders and patients.ā Graul continued, āCyclerionās diligence team, comprised of committed external experts in their respective fields, is currently in advanced stages of conducting promising asset evaluations, which we believe have the potential to be the new foundation for Cyclerion.ā
Cyclerion and Akebia have re-negotiated a mutually beneficial amendment to their exclusive license agreement for praliciguat, a systemic sGC stimulator. Under the new license amendment with Akebia, Cyclerion will receive $1.75 million in upfront and near-term payments. In addition, Akebia will assume responsibility for all intellectual property expenses associated with praliciguat after Q1 2025. In 2021, Akebia paid a $3.0 million upfront payment to the Company upon signing of the license agreement, and the Company is eligible to receive additional milestone cash payments of up to approximately $560 million in total potential future development, regulatory, and commercialization milestone payments for praliciguat. In exchange for a reduction in certain development milestone payments, Cyclerion is eligible to receive certain higher, tiered, sales-based royalties ranging from mid-single-digits to twenty percent.
Cyclerion has also entered into an exclusive license option agreement for its vascular sGC stimulator, olinciguat, with a separate entity, wholly controlled by CVCO Therapeutics, Inc., a clinical stage company focused on microvascular dysfunction in cardiovascular, inflammatory and metabolic disease states. Under the terms of the agreement, the potential partner has exclusive rights to evaluate olinciguat during the option period. During the option period, the grantee has assumed responsibility for all ongoing intellectual property-related expenses associated with olinciguat.
As part of its strategic initiatives, Cyclerion previously announced a definitive agreement for the sale of its CNS assets zagociguat and CY3018 to Tisento Therapeutics in May 2023 for an $8 million cash payment and a 10% equity stake in Tisento. The amended agreement for praliciguat, and if the option for olinciguat is exercised, would represent the likely final steps in the monetization of Cyclerionās historical portfolio. Cyclerion believes it is well positioned for the next phase in its overall strategy, to bring in new CNS assets to rebuild the pipeline.
georgie18
4 weeks ago
CYCN...$4.09...Off my $3.24 Alert...Price catching up to the News here...🥳
georgie18
Member Level
Re: georgie18 post# 670922
Thursday, January 30, 2025 8:01:17 PM
Post#
672876
of 672918
CYCN...$3.80...🥳...Off my $3.24 Alert...
georgie18
Member Level
Re: None
Thursday, January 09, 2025 9:18:16 AM
Post#
73
of 74
CYCN...$3.24...🥳... https://schrts.co/BZqjIquT ...Float in 2 Million range...CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced an update on its progress in catalyzing the Companyās next stage of growth. The Company is leveraging its legacy soluble guanylate cyclase (sGC) stimulator assets to generate near-term revenues which will be used to implement its strategic building plan without near-term dilution.
āThese agreements demonstrate Cyclerionās progress in maximizing its legacy asset value while redirecting resources toward acquiring potential new assets,ā said Regina Graul, Ph.D., President and Chief Executive Officer of Cyclerion. āThese newly finalized agreements, combined with our significant reduction of operating expenses, enable the focused use of our capital to support our anticipated pipeline build in the central nervous system (CNS) space. Concurrently, we plan to raise capital, as needed, to fund our product plans to create value for shareholders and patients.ā Graul continued, āCyclerionās diligence team, comprised of committed external experts in their respective fields, is currently in advanced stages of conducting promising asset evaluations, which we believe have the potential to be the new foundation for Cyclerion.ā
Cyclerion and Akebia have re-negotiated a mutually beneficial amendment to their exclusive license agreement for praliciguat, a systemic sGC stimulator. Under the new license amendment with Akebia, Cyclerion will receive $1.75 million in upfront and near-term payments. In addition, Akebia will assume responsibility for all intellectual property expenses associated with praliciguat after Q1 2025. In 2021, Akebia paid a $3.0 million upfront payment to the Company upon signing of the license agreement, and the Company is eligible to receive additional milestone cash payments of up to approximately $560 million in total potential future development, regulatory, and commercialization milestone payments for praliciguat. In exchange for a reduction in certain development milestone payments, Cyclerion is eligible to receive certain higher, tiered, sales-based royalties ranging from mid-single-digits to twenty percent.
Cyclerion has also entered into an exclusive license option agreement for its vascular sGC stimulator, olinciguat, with a separate entity, wholly controlled by CVCO Therapeutics, Inc., a clinical stage company focused on microvascular dysfunction in cardiovascular, inflammatory and metabolic disease states. Under the terms of the agreement, the potential partner has exclusive rights to evaluate olinciguat during the option period. During the option period, the grantee has assumed responsibility for all ongoing intellectual property-related expenses associated with olinciguat.
As part of its strategic initiatives, Cyclerion previously announced a definitive agreement for the sale of its CNS assets zagociguat and CY3018 to Tisento Therapeutics in May 2023 for an $8 million cash payment and a 10% equity stake in Tisento. The amended agreement for praliciguat, and if the option for olinciguat is exercised, would represent the likely final steps in the monetization of Cyclerionās historical portfolio. Cyclerion believes it is well positioned for the next phase in its overall strategy, to bring in new CNS assets to rebuild the pipeline.
georgie18
4 weeks ago
CYCN...$3.80...🥳...Off my $3.24 Alert...
georgie18
Member Level
Re: None
Thursday, January 09, 2025 9:18:16 AM
Post#
73
of 74
CYCN...$3.24...🥳... https://schrts.co/BZqjIquT ...Float in 2 Million range...CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced an update on its progress in catalyzing the Companyās next stage of growth. The Company is leveraging its legacy soluble guanylate cyclase (sGC) stimulator assets to generate near-term revenues which will be used to implement its strategic building plan without near-term dilution.
āThese agreements demonstrate Cyclerionās progress in maximizing its legacy asset value while redirecting resources toward acquiring potential new assets,ā said Regina Graul, Ph.D., President and Chief Executive Officer of Cyclerion. āThese newly finalized agreements, combined with our significant reduction of operating expenses, enable the focused use of our capital to support our anticipated pipeline build in the central nervous system (CNS) space. Concurrently, we plan to raise capital, as needed, to fund our product plans to create value for shareholders and patients.ā Graul continued, āCyclerionās diligence team, comprised of committed external experts in their respective fields, is currently in advanced stages of conducting promising asset evaluations, which we believe have the potential to be the new foundation for Cyclerion.ā
Cyclerion and Akebia have re-negotiated a mutually beneficial amendment to their exclusive license agreement for praliciguat, a systemic sGC stimulator. Under the new license amendment with Akebia, Cyclerion will receive $1.75 million in upfront and near-term payments. In addition, Akebia will assume responsibility for all intellectual property expenses associated with praliciguat after Q1 2025. In 2021, Akebia paid a $3.0 million upfront payment to the Company upon signing of the license agreement, and the Company is eligible to receive additional milestone cash payments of up to approximately $560 million in total potential future development, regulatory, and commercialization milestone payments for praliciguat. In exchange for a reduction in certain development milestone payments, Cyclerion is eligible to receive certain higher, tiered, sales-based royalties ranging from mid-single-digits to twenty percent.
Cyclerion has also entered into an exclusive license option agreement for its vascular sGC stimulator, olinciguat, with a separate entity, wholly controlled by CVCO Therapeutics, Inc., a clinical stage company focused on microvascular dysfunction in cardiovascular, inflammatory and metabolic disease states. Under the terms of the agreement, the potential partner has exclusive rights to evaluate olinciguat during the option period. During the option period, the grantee has assumed responsibility for all ongoing intellectual property-related expenses associated with olinciguat.
As part of its strategic initiatives, Cyclerion previously announced a definitive agreement for the sale of its CNS assets zagociguat and CY3018 to Tisento Therapeutics in May 2023 for an $8 million cash payment and a 10% equity stake in Tisento. The amended agreement for praliciguat, and if the option for olinciguat is exercised, would represent the likely final steps in the monetization of Cyclerionās historical portfolio. Cyclerion believes it is well positioned for the next phase in its overall strategy, to bring in new CNS assets to rebuild the pipeline.
georgie18
2 months ago
CYCN...$3.24...🥳... https://schrts.co/BZqjIquT ...Float in 2 Million range...CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced an update on its progress in catalyzing the Companyās next stage of growth. The Company is leveraging its legacy soluble guanylate cyclase (sGC) stimulator assets to generate near-term revenues which will be used to implement its strategic building plan without near-term dilution.
āThese agreements demonstrate Cyclerionās progress in maximizing its legacy asset value while redirecting resources toward acquiring potential new assets,ā said Regina Graul, Ph.D., President and Chief Executive Officer of Cyclerion. āThese newly finalized agreements, combined with our significant reduction of operating expenses, enable the focused use of our capital to support our anticipated pipeline build in the central nervous system (CNS) space. Concurrently, we plan to raise capital, as needed, to fund our product plans to create value for shareholders and patients.ā Graul continued, āCyclerionās diligence team, comprised of committed external experts in their respective fields, is currently in advanced stages of conducting promising asset evaluations, which we believe have the potential to be the new foundation for Cyclerion.ā
Cyclerion and Akebia have re-negotiated a mutually beneficial amendment to their exclusive license agreement for praliciguat, a systemic sGC stimulator. Under the new license amendment with Akebia, Cyclerion will receive $1.75 million in upfront and near-term payments. In addition, Akebia will assume responsibility for all intellectual property expenses associated with praliciguat after Q1 2025. In 2021, Akebia paid a $3.0 million upfront payment to the Company upon signing of the license agreement, and the Company is eligible to receive additional milestone cash payments of up to approximately $560 million in total potential future development, regulatory, and commercialization milestone payments for praliciguat. In exchange for a reduction in certain development milestone payments, Cyclerion is eligible to receive certain higher, tiered, sales-based royalties ranging from mid-single-digits to twenty percent.
Cyclerion has also entered into an exclusive license option agreement for its vascular sGC stimulator, olinciguat, with a separate entity, wholly controlled by CVCO Therapeutics, Inc., a clinical stage company focused on microvascular dysfunction in cardiovascular, inflammatory and metabolic disease states. Under the terms of the agreement, the potential partner has exclusive rights to evaluate olinciguat during the option period. During the option period, the grantee has assumed responsibility for all ongoing intellectual property-related expenses associated with olinciguat.
As part of its strategic initiatives, Cyclerion previously announced a definitive agreement for the sale of its CNS assets zagociguat and CY3018 to Tisento Therapeutics in May 2023 for an $8 million cash payment and a 10% equity stake in Tisento. The amended agreement for praliciguat, and if the option for olinciguat is exercised, would represent the likely final steps in the monetization of Cyclerionās historical portfolio. Cyclerion believes it is well positioned for the next phase in its overall strategy, to bring in new CNS assets to rebuild the pipeline.
Level up your trading with our powerful tools and real-time insights all in one place.
glenn1919
3 weeks ago
tw0122
4 weeks ago
LowFloatLopes
3 months ago
Strukture
3 months ago
PonkenPlonken
3 months ago
ecmoney
3 months ago
Hot Features
Premium
